Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas†.

Date publication

décembre 2016

Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Pr FALCOZ Pierre-Emmanuel

Tous les auteurs :
Guerrera F, Renaud S, Tabbó F, Voegeli' AC, Filosso PL, Legrain M, Boita M, Schaeffer M, Beau-Faller M, Ruffini E, Falcoz PE, Inghirami G, Oliaro A, Massard G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28329143

Résumé

The impact of skip N2 metastases (i.e. N2 lymph node metastases without N1) on survival in surgically resected non-small lung cancer remains an intriguing and rarely investigated topic. The goal of our study was to elucidate (i) skip N2 influence on overall survival (OS) and time to recurrence (TTR) in patients with resected lung adenocarcinoma and (ii) its link with epidermal growth factor receptor ( EGFR ) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutations.

Référence

Eur J Cardiothorac Surg. 2016 Dec;: